Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 10/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689659 | 0.89 | MAPT (0.88) | MAPTLMNATP53POLB | |
| SCHEMBL19708625 | 0.88 | MAPT (0.69) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL19689645 | 0.87 | MAPT (0.73) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL25779970 | 0.72 | LMNA (0.69) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL19689738 | 0.71 | MAPT (0.51) | MAPTPOLBTHRB | |
| SCHEMBL25780872 | 0.69 | LMNA (0.73) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL2262568 | 0.65 | GAA (0.64) | MAPTLMNATP53 | |
| SCHEMBL25779974 | 0.65 | IDO1 (0.78) | MAPTLMNATP53THRB | |
| SCHEMBL25779972 | 0.65 | LMNA (0.66) | MAPTLMNATP53THRB | |
| SCHEMBL25780435 | 0.64 | IDO1 (0.90) | MAPTLMNATP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3468965-B1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | LILLY CO ELI (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY | 2019-05-30 | — | — | US | disclosed |
| EP-3468965-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | Eli Lilly and Company (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9872853-B2 | 2,3-dihydro-1H-indole compounds | ELI LILLY AND COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY | 2017-12-14 | — | — | US | disclosed |
| WO-2017213919-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | MCL1, IDO1, GLI1 | MAPT 3345/4885LMNA 3574/4885TP53 12/4885 |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | MCL1, FOXM1, IDO1 | MAPT 3015/4885LMNA 4005/4885TP53 4/4885 |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | MCL1, IDO1, IDO2 | MAPT 3006/4885LMNA 3499/4885TP53 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.